Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free CALA Stock Alerts

Calithera Biosciences (CALA) Competitors

Calithera Biosciences logo
$0.0003 0.00 (0.00%)
As of 07/24/2026
Compare

CALA vs. ADTX, CMRA, SYRS, EVLO, and EFTR

Should you buy Calithera Biosciences stock or one of its competitors? MarketBeat compares Calithera Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calithera Biosciences include Aditxt (ADTX), Comera Life Sciences (CMRA), Syros Pharmaceuticals (SYRS), Evelo Biosciences (EVLO), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry.

How does Calithera Biosciences compare to Aditxt?

Calithera Biosciences (NASDAQ:CALA) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Calithera Biosciences has higher earnings, but lower revenue than Aditxt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Aditxt$14.34K0.20-$41.71M-$100.79 thousandN/A

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Aditxt Neutral

15.5% of Aditxt shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Calithera Biosciences has a beta of -1.36, meaning that its share price is 236% less volatile than the broader market. Comparatively, Aditxt has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market.

Calithera Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Calithera Biosciences' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calithera Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Calithera Biosciences and Aditxt tied by winning 5 of the 10 factors compared between the two stocks.

How does Calithera Biosciences compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Calithera Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Comera Life Sciences has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Comera Life Sciences has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.36, suggesting that its stock price is 236% less volatile than the broader market.

Summary

Comera Life Sciences beats Calithera Biosciences on 3 of the 4 factors compared between the two stocks.

How does Calithera Biosciences compare to Syros Pharmaceuticals?

Calithera Biosciences (NASDAQ:CALA) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Syros Pharmaceuticals Neutral

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Calithera Biosciences has a beta of -1.36, indicating that its stock price is 236% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

Calithera Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Calithera Biosciences has higher earnings, but lower revenue than Syros Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

Summary

Syros Pharmaceuticals beats Calithera Biosciences on 5 of the 8 factors compared between the two stocks.

How does Calithera Biosciences compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Calithera Biosciences Neutral

0.3% of Evelo Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Evelo Biosciences has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.36, indicating that its stock price is 236% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Summary

Evelo Biosciences beats Calithera Biosciences on 3 of the 5 factors compared between the two stocks.

How does Calithera Biosciences compare to eFFECTOR Therapeutics?

Calithera Biosciences (NASDAQ:CALA) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
eFFECTOR Therapeutics Neutral

Calithera Biosciences has a beta of -1.36, suggesting that its stock price is 236% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Summary

eFFECTOR Therapeutics beats Calithera Biosciences on 4 of the 5 factors compared between the two stocks.

Get Calithera Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALA vs. The Competition

Export
MetricCalithera BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$975.85M$6.87B$12.26B
Dividend YieldN/A4.84%2.67%9.79%
P/E Ratio0.001.5327.1423.64
Price / SalesN/A104.46517.0889.45
Price / CashN/A20.0650.5459.64
Price / BookN/A8.4710.286.07
Net Income-$39.65M-$2.70M$3.60B$331.99M
7 Day PerformanceN/A-2.29%-1.27%-0.63%
1 Month PerformanceN/A-3.97%-0.37%-2.00%
1 Year PerformanceN/A27.39%18.30%13.62%

Calithera Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALA
Calithera Biosciences
N/A$0.00
flat		N/AN/A$1KN/AN/A60
ADTX
Aditxt
0.1514 of 5 stars		$0.00
-5.7%		N/A-100.0%$3K$14.34KN/A60
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
SYRS
Syros Pharmaceuticals
N/A$0.00
-50.0%		N/A-99.5%$3K$386KN/A120
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CALA) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel